- Home
- BRLS vs CLLS Comparison
BRLS vs CLLS Comparison
Compare BRLS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLS
- CLLS
- Stock Information
- Founded
- BRLS 2019
- CLLS 1999
- Country
- BRLS Canada
- CLLS France
- Employees
- BRLS N/A
- CLLS N/A
- Industry
- BRLS
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- BRLS
- CLLS Health Care
- Exchange
- BRLS NYSE
- CLLS Nasdaq
- Market Cap
- BRLS 130.4M
- CLLS 143.4M
- IPO Year
- BRLS N/A
- CLLS 2007
- Fundamental
- Price
- BRLS $4.75
- CLLS $1.47
- Analyst Decision
- BRLS
- CLLS Buy
- Analyst Count
- BRLS 0
- CLLS 2
- Target Price
- BRLS N/A
- CLLS $7.00
- AVG Volume (30 Days)
- BRLS 142.8K
- CLLS 53.4K
- Earning Date
- BRLS 08-13-2025
- CLLS 08-05-2025
- Dividend Yield
- BRLS N/A
- CLLS N/A
- EPS Growth
- BRLS N/A
- CLLS N/A
- EPS
- BRLS N/A
- CLLS N/A
- Revenue
- BRLS $26,619,131.00
- CLLS $54,747,000.00
- Revenue This Year
- BRLS N/A
- CLLS $48.52
- Revenue Next Year
- BRLS N/A
- CLLS $5.17
- P/E Ratio
- BRLS N/A
- CLLS N/A
- Revenue Growth
- BRLS N/A
- CLLS 351.26
- 52 Week Low
- BRLS $3.00
- CLLS $1.10
- 52 Week High
- BRLS $9.47
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- BRLS 48.52
- CLLS 53.84
- Support Level
- BRLS $4.45
- CLLS $1.33
- Resistance Level
- BRLS $6.26
- CLLS $1.46
- Average True Range (ATR)
- BRLS 0.93
- CLLS 0.07
- MACD
- BRLS 0.10
- CLLS 0.00
- Stochastic Oscillator
- BRLS 36.64
- CLLS 64.13
About BRLS BOREALIS FOODS INC
Borealis Foods Inc is a food technology company that has developed high-quality, affordable, sustainable, and nutritious ready-to-eat meals. It is a mission-driven company committed to utilizing its products to help solve national and global food security and nutrition challenges. Its commitment to nutrition, affordability, and sustainability reflects its goal of positively impacting both human life and the planet. Through the development and launch of its ready-made ramen, featuring 20 grams of complete plant-based protein per serving, Borealis is developing advanced solutions to address global food challenges.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.